Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2026-03-16
Target enrollment:
Participant gender:
Summary
The study included 110 RCC patients who were at high risk for recurrence after nephrectomy
(T2G3-4 or T3-4 or N1) or oligometastasis who were scheduled to receive radical topical
therapy (M1 NEG). They were randomly divided to receive axitinib plus PD-1 + surgery or
surgery alone at a ratio of 1:1, so as to determine the efficacy of the neoadjuvant
combination of axitinib plus PD-1.